Variant Creutzfeldt-Jakob disease (vCJD) is a human prion disease resulting from the consumption of meat products contaminated by the agent causing bovine spongiform encephalopathy. Evidence supporting the presence of a population of silent carriers that can potentially transmit the disease through blood transfusion is increasing. The development of a blood-screening assay for both symptomatic vCJD patients and asymptomatic carriers is urgently required. We show that a diagnostic assay combining plasminogen-bead capture and protein misfolding cyclic amplification (PMCA) technologies consistently detected minute amounts of abnormal prion protein from French and British vCJD cases in the required femtomolar range. This assay allowed the blinded identification of 18 patients with clinical vCJD among 256 plasma samples from the two most affected countries, with 100% sensitivity [95% confidence interval (CI), 81.5 to 100%], 99.2% analytical specificity (95% CI, 95.9 to 100%), and 100% diagnostic specificity (95% CI, 96.5 to 100%). This assay also allowed the detection of silent carriage of prions 1.3 and 2.6 years before the clinical onset in two blood donors who later developed vCJD. These data provide a key step toward the validation of this PMCA technology as a blood-based diagnostic test for vCJD and support its potential for detecting presymptomatic patients, a prerequisite for limiting the risk of vCJD transmission through blood transfusion.
INTRODUCTION
Variant Creutzfeldt-Jakob disease (vCJD) was identified in 1996 in the U.K. as a zoonotic infection caused by the dietary transmission of bovine spongiform encephalopathy (1, 2) . vCJD is a rare transmissible spongiform encephalopathy (TSE) with a long incubation period and with no validated test to identify affected individuals before clinical onset. Until recently, all clinical cases of vCJD evaluated for the prion protein gene (PRNP) were homozygous for methionine at codon 129 (59% of the Caucasian population) (3) with no cases in the alternative genotypes. The first confirmed vCJD clinical case in a patient heterozygous for methionine/valine has just been reported in the U.K. (4) . Patients with vCJD display an accumulation of abnormally folded prion protein (PrP TSE ) in the brain and lymphoid tissues including the spleen, lymph nodes, appendix, and tonsils (5, 6) , raising concerns about the risk of blood-borne infection. The secondary transmission of prions through blood has been demonstrated in several animal models (7) (8) (9) (10) . In the U.K., four cases of infection by the vCJD agent have been reported in recipients of nonleukodepleted red blood cell concentrate from donors who were carriers for vCJD (11) (12) (13) . A fifth probable case was reported in a patient with hemophilia treated with coagulation factor VIII manufactured from plasma derived from U.K. donors (14) . Infectivity in blood is thought to be split about equally between leukocytes and plasma, with negligible amounts directly associated with red blood cells or platelets (15) . Whereas clinical cases of vCJD are declining worldwide, the prevalence of asymptomatic carriers in the general population remains a concern. Investigations into the prevalence of asymptomatic carriers, using immunohistochemical detection of PrP TSE in a large series of appendix specimens, indicated an unexpectedly high rate of infection (1/2000) in the general U.K. population (16, 17) , which can be extrapolated to a prevalence of 1/20,000 in France where the level of exposure is considered to be 10 times lower. Detecting circulating agents in asymptomatic subjects with peripheral prion infection is thus important for public health, in particular to avoid secondary transmission through blood transfusion. A prototype enzymelinked immunosorbent assay (ELISA) test was recently reported to identify vCJD cases by probing whole blood (18) (19) (20) . Several other strategies are being explored using blood (21) (22) (23) and urine from vCJD patients (24) . However, most blood tests have only reached about 70% sensitivity in blinded studies, thus falling short of the acceptance criteria of 90% required by the European Union (EU) Commission Directive 2011/100/EU for licensing for human use (25) . In addition, none of these tests has proven effective for detecting presymptomatic patients. We have previously described a blood diagnostic assay based on serial prion amplification by protein misfolding cyclic amplification (PMCA) (26) . To circumvent the presence of blood-associated conversion inhibitors, we first captured the prion protein using magnetic nanobeads coated with plasminogen. Plasminogen was identified as a ligand of abnormal prion proteins using specific interactions with lysine residues by Fischer et al. (27) . Of particular interest is the capacity of plasminogen to bind to PrP TSE from various species including humans as well as sporadic CJD (sCJD) prions (28) . Plasminogen has also demonstrated the ability to stimulate prion conversion in vitro (29) .
In our PMCA-based assay (30) , the capture step enables the concentration of prion proteins present in 500 ml of plasma and their separation from blood-associated conversion inhibitors. Our assay has already achieved the level of performance required to detect PrP TSE at the femtomolar range in plasma, buffy coat, or whole-blood samples using either citrate or EDTA as anticoagulant. Here, by testing rare specimens from U.K. and French CJD surveillance centers, we further assess the performance of our assay against the strict requirements outlined in the amended Decision 2002/364/EC of the European Directive 98/79/EC (25) regarding the common technical specifications for vCJD blood-screening assays. Our assay allowed us to diagnose in a blinded fashion the presence of PrP TSE in samples from 18 of 18 symptomatic vCJD cases among a large sample collection, including samples from patients with sCJD, with 100% sensitivity. It also permitted PrP TSE detection in plasma samples collected 14 and 31 months before clinical onset in two French blood donors who later developed vCJD.
RESULTS
Analytical sensitivity of the vCJD diagnostic assay Our vCJD diagnostic assay consisted of a plasminogen-bead capture step followed by serial PMCA (Fig. 1) . We validated our vCJD assay for analytical sensitivity (test detection threshold) using a blinded reference panel consisting of plasma (in citrate anticoagulant) spiked with World Health Organization (WHO) reference materials from the National Institute for Biological Standards and Control (NIBSC) (NHBY0/0003 for brain and NHSY0/0009 for spleen from vCJD patients) (30) .To refine these sensitivity data, we prepared an additional panel of human plasma samples spiked with serial dilutions of the same vCJD WHO reference brain tissue ranging from 10 −5 to 10
. After three PMCA rounds of 80 cycles each, PrP TSE could be detected at a dilution of 10 −9 (Fig. 2 ). Additional rounds of PMCA did not increase this level of analytical sensitivity. The number of misfolded PrP TSE molecules in the 10 −10 dilution of the brain (and lower dilutions) and recovered by the plasminogen beads as the PMCA seed input was likely insufficient to initiate the amplification process. However, this 10 −9 dilution of analytical sensitivity is 4 to 5 log higher than the acceptance criteria of 10 −4 dilution required by the Common Technical Specifications defined in the European Commission Directive regarding the performances of vCJD screening assays (25) .
Diagnostic sensitivity and analytical specificity of the vCJD assay To evaluate the diagnostic sensitivity and the analytical specificity of our assay, we analyzed in a blinded fashion a total of 152 plasma samples from French and British patients, including 18 patients with vCJD, 67 with sCJD, and 67 with non-CJD neurological diseases. In addition, plasma samples from 104 blood donors were tested as healthy controls to evaluate diagnostic specificity (Table 1) .
Among the 152 plasma samples from patients, our assay blindly identified all 18 cases of clinical vCJD, thus achieving a diagnostic sensitivity of 100% [95% confidence interval (CI), 81.5 to 100]. As shown in Table 2 , of the 18 vCJD samples, 1 was positive after two rounds of PMCA, 8 were positive after three rounds of PMCA, and 9 were positive after four rounds. Whereas the detection limit was reached after three rounds of PMCA for brain material spiked into the plasma (exogenous prions), one additional round of PMCA increased the sensitivity of the assay when plasma samples from vCJD patients (endogenous prions) were tested. Blood samples were obtained for all patients shortly before death, except for five that were collected at earlier clinical phases of the disease. The number of rounds required to obtain a positive signal showed no correlation with the time at which the tested sample was collected before the patient's death. As shown in Table 1 , our assay also showed high analytical specificity, with only 1 of 134 potentially cross-reacting blood specimens from patients with sCJD, Alzheimer's disease, Parkinson's disease, and other neurological diseases giving a positive result (99.2% specificity; 95% CI, 95.9 to 100). The positive specimen was from a 65-year-old patient in the U.K. with sCJD (homozygous for methionine at codon 129 with a 2a molecular typing; type MM2a). Two other plasma samples from type MM2a sCJD patients were tested in this study and gave negative results for PrP (Table 1 ) even after five rounds of PMCA, thus indicating a diagnostic specificity of 100% (95% CI, 96.5 to 100).
We then compared by Western blotting the PrP TSE molecular signature obtained for the clinical vCJD amplified samples with that of the reference brain samples from patients with sCJD or vCJD (Figs. 3 and 4B). Samples from all the vCJD patients displayed the characteristic type 2 mobility (19 kDa) and clear predominance of the diglycosylated isoform (27 kDa), whether amplified from plasma ( Fig. 4B; vCJD plasma) or from crude brain tissue ( Fig. 4B ; vCJD brain homogenate). A similar type 2 mobility was also seen on the amplified products obtained from the U.K. patient samples (Fig. 3) , including the 10 vCJD samples and strikingly with the sCJD patient classified as MM2a [UK-14; Fig. 3 ].
Preclinical detection of abnormal prions in plasma
In France, since 1999, as an additional control for blood safety, two 500-ml nonleukodepleted aliquots of the plasma of all blood donations are archived in liquid nitrogen for 5 years by the Etablissement Français du Sang (French blood service). Three of the 27 patients who developed clinical signs of vCJD had been regular blood donors (cases 8, 9, and 13). Eleven sequential archived plasma vials from two of these three donors were traced and specifically archived for long-term conservation. These vials correspond to the seven last blood donations from donor A (case 8) and the four last donations from donor B (case 13). No archived samples could be traced for case 9. Donors A and B donated once or twice a year before they developed clinical signs of vCJD 7 and 2 months, respectively, after their last blood donation. Thus, we analyzed 11 nonleukodepleted plasma samples from donors A and B starting from 55 to 30 months, respectively, before clinical symptom onset. For donor A (Fig. 5A ), although the first four plasma samples (A1 to A4) were negative after six successive rounds of PMCA, we detected PrP TSE 31 months before clinical onset (A5) and in subsequent blood donations (A6 and A7) after three or four PMCA rounds. In donor B, after six PMCA rounds, PrP TSE detection was negative 30 months before clinical onset (B1) and became positive 14 months later (B2), which was 16 months before the appearance of clinical signs of the disease (Fig. 5B) . Subsequent blood donations (B3 and B4) were also positive for vCJD prions after three or four PMCA rounds. These results demonstrate the presence of PrP TSE in the plasma of individuals during the presymptomatic phase of vCJD.
DISCUSSION
Here, we report a detection method in plasma allowing the diagnosis of clinical vCJD with 100% sensitivity, 99.2% analytical specificity, and 100% diagnostic specificity. Despite the rarity of the samples, we have tested 18 blood samples from vCJD patients from France and the U.K. Eighteen of 18 clinical vCJD cases were identified in a blinded fashion. Such results satisfy the requirements for both sensitivity and specificity mandated by the European Commission Directive (25) . In a related study in this issue, Concha-Marambio et al. provided further support for the validity of the PMCA technology for detecting vCJD in human blood samples with 100% sensitivity and specificity (31) .
The finding that 1 of 67 sCJD patients tested positive for PrP TSE in plasma may suggest that our assay could sporadically amplify type MM2a PrP TSE under conditions optimized for vCJD detection. The presence of infectivity in the blood of patients with sCJD has recently been reported (32) but requires further investigation. Jackson et al. (20) , when determining the diagnostic performance of their prototype vCJD ELISA blood test, also found two patients with sCJD who tested positive, indicating some reactivity of their assay for sCJD in whole blood. Lastly, and as suggested by the results obtained in prevalence studies on appendix tissue (16), we cannot exclude the possibility that the MM2a U.K. sCJD patient testing positive in our assay was also a carrier of vCJD infection in lymphoid tissue. No peripheral tissues are available from this case to investigate this hypothesis. Using recombinant PrP as a substrate instead of brain homogenate and intensive agitation instead of sonication, an alternative method called real-time quaking-induced conversion (RT-QuIC) has emerged as a powerful tool for prion detection (33, 34) . Independent studies have shown that the detection in the cerebrospinal fluid or in the olfactory epithelium of PrP TSE for the diagnosis of sCJD by RT-QuIC may be 99 to 100% specific (35) (36) (37) . However, as yet, RT-QuIC appears to be less efficient in detecting PrP TSE from vCJD patients using various full-length recombinant PrP (38) , although the use of hamstersheep chimeric PrP may improve its sensitivity (22) . From a clinical point of view, to date, RT-QuIC-derived methods have not been used to diagnose vCJD. Two detection assays have been described for the detection of vCJD prions in blood with sensitivities close to 70%. The first one combines a solid-state binding matrix to capture and concentrate PrP TSE from whole-blood samples with direct immunodetection (18) . Having demonstrated 98.1% analytical specificity (95% CI, 93.3 to 99.8%) with two sCJD positives detected and 100% diagnostic specificity (95% CI, 99.9 to 100%) in 5000 U.S. blood donor samples (20) , this assay appears promising as a screening assay. The second assay is a PMCA-based assay that has allowed the detection of PrP TSE in white blood cells from three of four patients with clinical vCJD (21) . The diagnosis of vCJD may also be achieved using urine samples according to a third PMCA-based assay (24) , which has also shown promising results: 92.9% sensitivity on 14 symptomatic vCJD patient samples (95% CI, 66.1 to 99.8%) and 100% diagnostic specificity on 52 healthy control samples (95% CI, 93.2 to 100%). There is no evidence that these assays can detect PrP TSE in carriers incubating the disease, who have not yet shown clinical symptoms.
Here, we report the identification of asymptomatic patients with detectable PrP TSE in the blood before clinical onset. The observed kinetics of the appearance of detectable PrP TSE in plasma indicates that a presymptomatic diagnosis is possible up to 31 months before the first clinical symptoms appear. This is consistent with the intervals of 17 to 40 months between the blood donations most likely responsible for secondary vCJD transmission in the U.K. and the onset of vCJD symptoms observed in the corresponding donors (11, 13, 39) . The number of PMCA rounds required to obtain a positive signal varied between three and four during the incubation period in each Presymptomatic vCJD*** 2/2 *U.K. patient aged 65 years, sCJD type MM2a. **Epilepsy (n = 2), brain anoxia (n = 2), psychiatric diseases (n = 2), celiac disease (n = 1), cerebellar ataxia (n = 1), confusion (n = 1), and polyradiculoneuropathy (n = 1). ***Both patients are distinct from the eight French patients with clinical vCJD sampled during the clinical course of the disease.
asymptomatic case and between two and four after clinical onset. TSE with seeding activity can be found in the blood of humans at a presymptomatic stage. This has profound implications for public health and risk management, particularly in transfusion medicine. Our results provide a first estimation of the level of circulating abnormal prions in the plasma of patients in the final years of the incubation period for vCJD, which is not dissimilar from that observed in symptomatic patients. In France, no case of transfusion-transmitted vCJD has been reported so far in patients treated with blood products from the three vCJD patients who donated before symptom onset. This observation suggests that the precautionary measures introduced in France to safeguard blood transfusion, in particular leukodepletion, may have reduced the risk of transmission. With a limit of detection in the femtomolar range, our assay should allow a more precise evaluation of the residual risk of vCJD prion distribution in the different blood components. It may also be well suited for use as a complementary confirmatory assay, ensuring that any positive results from high-throughput bloodscreening assays are true positives.
From a clinical point of view, a diagnostic method with 100% sensitivity is of special interest for diagnosis in young patients showing clinical signs that do not fulfill the criteria of probable vCJD or in older patients with atypical forms of rapidly progressive dementia (42) .
There are some limitations to our study. Only a limited number of blood samples from vCJD patients with clinical disease were tested, but the number of samples in this study nonetheless fulfilled the requirements of the European Commission Directive (25) because vCJD is a very rare disease. In addition, the number of 18 symptomatic vCJD patients is within the range of recent international studies in the field of vCJD diagnosis (18, 24) . Our study demonstrated the presence of PrP TSE in the plasma in only two presymptomatic vCJD cases, but samples of such presymptomatic blood donors are rare, and their inclusion provided a unique opportunity to assess the kinetics of PrP TSE presence in blood during the incubation period. Until recently, all patients with clinical vCJD worldwide, including those enrolled in the present study (table S1), have been methionine-homozygous at codon 129 of the PRNP gene. The potential for infection to occur in lymphoid tissues and in the central nervous system in the other genotypes at codon 129 is supported by the observation of PrP TSE accumulation in the lymphoid tissues of an asymptomatic heterozygous recipient of a potentially contaminated blood transfusion (12) and the recent report of the first vCJD case in a heterozygous patient (4) . In addition, 50% of the asymptomatic carriers identified in the prevalence study on appendix tissues (16) were not homozygous for methionine at codon 129. Although the present study is an important first step for the systematic detection of infected individuals, with a significant potential impact on transfusion safety, whether the assay could detect PrP TSE in the blood of vCJD patients with other genotypes has yet to be confirmed.
In conclusion, our results provide valuable data on circulating abnormal prion proteins during the incubation phase in humans and validate a new protein misfolding amplification-based assay that will reduce the potential risk of vCJD secondary transmission. Moreover, beyond these public health issues, our study provides evidence that a brain proteinopathy responsible for neurodegenerative disease can be diagnosed in asymptomatic patients through the detection of circulating abnormal protein aggregates. This finding is of interest for future translational research in neurological diseases caused by protein misfolding and aggregation, such as Alzheimer's disease and Parkinson's disease, for which there is a major need for a noninvasive early diagnostic test.
MATERIALS AND METHODS

Study design
The aim of the study was to investigate the suitability of our blood diagnostic assay comprising plasminogen-bead capture coupled with PMCA to identify vCJD-infected individuals. Compared with the handling of an emerging viral infection, development of a screening assay for infectious prions that in addition can be applied to blood samples from asymptomatic patients is challenging. In particular, only a small number of blood samples are available from clinical cases in France; no seroconversion panels are available nor a gold standard assay against which candidate-screening assays can be compared. From a regulatory point of view, vCJD assays for blood screening, diagnosis, and confirmation have been added to List A of Annexe II to Directive 98/79/EC by the Commission Directive 2011/100/EU of the EU In Vitro Diagnostics Directive, meaning that candidate assays must meet strict requirements with regard to sensitivity and specificity (25) . Our study aimed to meet these acceptance criteria by testing plasma samples distributed in blinded panels from the U.K. and France. These panels included 18 plasma samples from vCJD patients, 134 potentially crossreacting plasma samples from patients with neurological disorders, and 104 plasma samples from French blood donors. The detectability . NBH refers to a negative control brain homogenate from a non-CJD plasma sample without any proteinase K digestion. The dashed line indicates separate Western blots.
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of PrP TSE in the blood of presymptomatic carriers was also assessed on 11 archived plasma vials from two blood donors who subsequently developed vCJD.
Normal plasma samples and reference brain tissues
To assess the diagnostic specificity, anonymized blood samples were collected from consenting French blood donors in compliance with French regulations (code de la santé publique article L.1243-3). Wholeblood samples (n = 104) were collected in EDTA-containing tubes. Plasma was isolated after centrifugation at 1500g for 15 min at 21°C and stored at −80°C until use.
For the study of analytical sensitivity, WHO reference brain samples (10%, w/v) were provided by the NIBSC (U.K.) under the reference number NHBY0/0003 for vCJD and number NHBX0/0001 for sCJD [ Blood sampling from cases with a suspected diagnosis of CJD notified to the surveillance network was initiated in June 2006. This collection is dedicated to the assessment of novel diagnostic procedures for CJD. An informed and signed consent from the patients or their relatives was obtained for each sample. The procedure was approved by the ethics committee of the Pitié-Salpêtriere Hospital (CCPPRB/130-05). Blood was sampled in tubes containing sodium citrate, heparin, or EDTA. After centrifugation at 2000g for 15 min at 4°C, plasma, buffy coat, and red blood cells were sampled in aliquots of 150 ml and stored at −80°C. Here, only EDTA plasma samples were used. Samples from 132 patients including 8 cases with vCJD (the last 8 cases on a total of 27 French cases who have died of vCJD), 57 cases with sCJD, and 67 cases with other neuropsychiatric diagnosis (see Table 1 ) were split up into six consecutive groups and provided blindly to undergo our testing procedure.
Blind panels from the U.K. National CJD Research and Surveillance Unit The National CJD Research and Surveillance Unit was established in 1990 and receives referrals of all suspect cases of CJD in the U.K. Whenever possible, staff from the unit visit the referred cases for assessment and collection of detailed medical data before classifying the cases using internationally recognized criteria (44, 45) . Only definite and probable CJD cases are reported to the EuroCJD network, and 
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all vCJD cases are reported to the European Centre for Disease Prevention and Control. Blood samples have been obtained in all cases since 1990. Informed and signed consent was provided by the patient or relatives. The study was approved by the National Health Service Lothian Ethics Committee. The blood samples were collected in EDTA or citrate. After centrifugation at 400g for 10 min, plasma, buffy coat, and red blood cells were stored at −80°C. Here, samples stored in citrate or EDTA were used. In eight vCJD samples, the type of anticoagulant, either EDTA or citrate, was not recorded. Samples included 10 from vCJD cases (of 178 cases of vCJD in the U.K.) and 10 from sCJD cases. The 20 samples were provided blinded to undergo the testing procedure.
Archived plasma panels from the Etablissement Français du Sang (French blood service) Since 1999, two aliquots of nonleukodepleted plasma from all blood donations are archived for 5 years by the Etablissement Français du Sang in liquid nitrogen to allow additional controls with regard to blood safety. These aliquots, each of 500 ml, are prepared from whole blood collected in EDTA-containing tubes. Eleven sequential archived plasma vials from two donors who later developed vCJD were traced and specifically archived for long-term conservation (over 5 years). These vials correspond to the last seven blood donations for the 8th vCJD French case (donor A) and the last four donations for the 13th vCJD French case (donor B). Nine archived plasma samples from blood donors who never developed CJD were added to this study.
Testing procedure
The testing procedure is a three-step assay (30) that captures PrP TSE from infected blood using plasminogen-coated magnetic nanobeads before serial amplification of PrP TSE via PMCA and finally specific detection by Western blot (Fig. 1) . Plasma samples were thawed in a water bath for 10 min at 37°C and clarified at 1500g for 5 min at 21°C. In the preanalytical capture step, 10 ml of 1% (w/v) beads (Ademtech) at 10 mg of plasminogen per milligram of beads was added to a mix (1:1) of plasma samples (400 to 500 ml) and ligation buffer [0.1 M phosphate, 0.5% sodium chloride, and 0.1% sarkosyl (pH 7.4)] before being incubated for 90 min at 25°C. After washing steps with phosphatebuffered saline, beads were directly resuspended in the PMCA substrate.
For the PMCA amplification, the source of PrP used as substrate was obtained from brain homogenates of healthy transgenic mice overexpressing sixfold more human PrP with a methionine at codon 129 (tg650 line) (46) . Brains were prepared at 10% (w/v) homogenate in converting buffer (phosphate-buffered saline containing 150 mM sodium chloride and 1% Triton) and clarified at 2000g for 20 s before freezing at −80°C in single-experiment aliquots of PMCA substrate.
The captured prion protein was mixed with 90 ml of PMCA substrate in PCR tubes containing three Teflon beads. Amplification (80 cycles) was performed by three different technicians using two different types of sonicators (S4000, Misonix, and Q700; Qsonica). Each cycle is composed of an incubation step (29 min 40 s at 37°C) and a sonication step (20 s at 240 W). Successive rounds of 80 cycles were performed by diluting the amplified material 1:10 in fresh PMCA substrate. To avoid any cross-contamination, experiments were carried out under strict quality-controlled PCR conditions. In addition, positive samples were not systematically subjected to an additional PMCA round.
After amplification, protease-resistant prion protein was detected by Western blot, as previously described (47) . Samples were incubated with proteinase K (200 mg/ml) for 60 min at 45°C before denaturation at 100°C in denaturing buffer. Samples were run on 12% polyacrylamide gel electrophoresis before being electrotransferred onto a polyvinylidene difluoride membrane and revealed using 3F4 or 12B2 monoclonal antibodies against prion protein.
Statistical analysis
Calculations of 95% Clopper-Pearson CIs for sensitivities and specificities were performed according to the exact binomial test (48) using the free software R (49).
SUPPLEMENTARY MATERIALS
www.sciencetranslationalmedicine.org/cgi/content/full/8/370/370ra182/DC1 Methods Table S1 . Codon 129 genotype of the patients included in this study (including presymptomatic cases). Reference (50) 
